{"id":50675,"date":"2025-03-06T14:54:53","date_gmt":"2025-03-06T06:54:53","guid":{"rendered":"https:\/\/biopioneer.com.tw\/?p=50675"},"modified":"2025-11-15T16:50:40","modified_gmt":"2025-11-15T08:50:40","slug":"ez-cap-firefly-luciferase-mrna-apexbio%e8%b2%a8%e8%99%9f-r1018","status":"publish","type":"post","link":"https:\/\/biopioneer.com.tw\/?p=50675","title":{"rendered":"EZ Cap\u2122 Firefly Luciferase mRNA APExBIO\u8ca8\u865f R1018"},"content":{"rendered":"<p><strong><span style=\"font-size: 12pt; color: #ff6600;\"><span style=\"font-size: 14pt;\"><span style=\"color: #800080;\">\u5831\u544a\u57fa\u56e0mRNA\u7cfb\u5217\u5546\u54c1-&gt;&gt;<span style=\"color: #ff6600;\">Firefly Luciferase mRNA<\/span><\/span><\/span><\/span><\/strong><\/p>\n<p>APExBIO Technology LLC \u662f\u4e00\u5bb6\u9818\u5148\u7684\u5c0f\u5206\u5b50\u6291\u5236\u5291(Small Molecule Inhibitors)\/\u6d3b\u5316\u5291(Activators)\u3001\u5316\u5408\u7269\u5eab( Compound Libraries)\u3001\u80dc\u80bd(Peptides)\u3001\u6aa2\u6e2c\u8a66\u5291\u76d2(Assay Kits)\u3001\u87a2\u5149\u6a19\u8a18(Fluorescent Label)\u3001\u9176(Enzymes)\u3001\u4fee\u98fe\u6838\u82f7\u9178(Modified Nucleotides)\u3001mRNA \u5408\u6210\u4ee5\u53ca\u5404\u7a2e\u5206\u5b50\u751f\u7269\u5b78\u5de5\u5177\u7684\u4f9b\u61c9\u5546\u3002APExBIO\u63d0\u4f9b\u5ee3\u6cdb\u7684\u7522\u54c1\u7dda\uff0c\u6db5\u84cb 20 \u591a\u500b\u4e0d\u540c\u7684\u7814\u7a76\u9818\u57df\uff0c\u4f8b\u5982\u764c\u75c7(cancer)\u3001\u514d\u75ab\u5b78(immunology)\u3001\u795e\u7d93\u79d1\u5b78(neurosciences)\u3001\u7d30\u80de\u51cb\u4ea1(apoptosis)\u548c\u8868\u89c0\u907a\u50b3\u5b78(epigenetics)\u7b49\u3002\u516c\u53f8\u7e3d\u90e8\u4f4d\u65bc\u7f8e\u570b\u5fb7\u5dde\u4f11\u58eb\u9813USA (Houston, Texas)\uff0c\u81f4\u529b\u65bc\u670d\u52d9\u5168\u7403\u5ba2\u6236\u3002\u9ad8\u5ea6\u91cd\u8996\u7522\u54c1\u54c1\u8cea\u3002\u6240\u6709\u7522\u54c1\u5747\u9075\u5faa\u56b4\u683c\u7684\u751f\u7522\u6307\u5357\uff0c\u4e26\u9644\u6709\u5206\u6790\u8b49\u66f8\u3001HPLC\u3001\u8cea\u8b5c(Mass Spectrum)\u548cHMNR\u4ee5\u53ca\u9ad4\u5916\u9a57\u8b49(in vitro validation)\u3002 APExBIO\u7522\u54c1\u5df2\u88ab\u300aNature\u300b\u3001\u300aCell\u300b\u548c\u300aScience\u300b\u7b49\u773e\u591a\u9802\u7d1a\u540c\u884c\u8a55\u5be9\u671f\u520a\u5f15\u7528\u3002<a href=\"https:\/\/biopioneer.com.tw\/?news=apexbio%e5%8f%b0%e7%81%a3%e4%bb%a3%e7%90%86%e5%95%86-brandagency%e4%bb%a3%e7%90%86%e5%93%81%e7%89%8c-apexbio-2\"><span style=\"color: #ff0000;\"><em><strong><span style=\"text-decoration: underline;\">&gt;&gt;\u66f4\u591aAPExBio\u5546\u54c1<\/span><\/strong><\/em><\/span><\/a><\/p>\n<p><img decoding=\"async\" loading=\"lazy\" class=\"\" src=\"https:\/\/biopioneer.com.tw\/wp-content\/uploads\/downloads\/2025\/06\/%E5%A4%AA%E9%BC%8E-APExBIO-Technology-LLC-%E5%93%81%E7%89%8C.png\" width=\"1099\" height=\"274\" \/><\/p>\n<p><span style=\"color: #33cccc;\"><a style=\"color: #33cccc;\" href=\"https:\/\/biopioneer.com.tw\/?p=50675&amp;preview=true\"><span style=\"font-size: 12pt;\"><strong>EZ Cap\u2122 Firefly Luciferase mRNA APExBIO\u8ca8\u865f R1018<\/strong><\/span><\/a><\/span><\/p>\n<p><span style=\"color: #800000;\"><strong><span style=\"font-size: 12pt;\">EZ Cap\u2122 Firefly Luciferase mRNA\u7522\u54c1\u4ecb\u7d39<\/span><\/strong><\/span><\/p>\n<p>Firefly Luciferase mRNA with Cap 1 structure, providing higher transcription efficiency and enhanced stability.<\/p>\n<p>EZ Cap\u2122 \u87a2\u706b\u87f2\u87a2\u5149\u7d20\u9176 mRNA (EZ Cap\u2122 Firefly Luciferase mRNA) \u9032\u5165\u7d30\u80de\u5f8c\u6703\u8868\u73fe\u87a2\u5149\u7d20\u9176\u86cb\u767d\uff0c\u8a72\u86cb\u767d\u6700\u521d\u662f\u5f9e\u87a2\u706b\u87f2 Photinuspyralis \u4e2d\u63d0\u53d6\u7684\u3002\u6b64\u9175\u7d20\u50ac\u5316 ATP \u4f9d\u8cf4\u6027 D-\u87a2\u5149\u7d20\u6c27\u5316\u4e26\u5c0e\u81f4\u5728\u7d04 560 nm \u6ce2\u9577\u8655\u7522\u751f\u5316\u5b78\u767c\u5149\u3002\u87a2\u706b\u87f2\u87a2\u5149\u7d20\u9176 (Firefly Luciferase)\u662f\u4e00\u7a2e\u5e38\u7528\u65bc\u57fa\u56e0\u8abf\u63a7\u548c\u529f\u80fd\u7814\u7a76\u7684\u751f\u7269\u767c\u5149\u5831\u544a\u57fa\u56e0\u3002\u5b83\u9069\u7528\u65bc mRNA \u905e\u9001 (mRNA delivery)\u3001\u7ffb\u8b6f\u6548\u7387(translation efficiency)\u3001\u7d30\u80de\u6d3b\u529b(cell viability)\u548c\u9ad4\u5167\u6210\u50cf( in vivo imaging)\u7b49\u6aa2\u6e2c\u3002\u76ee\u524d\u5c0dmRNA\u52a0\u5e3d\u7684\u65b9\u6cd5\u6709\u5169\u7a2e\uff1a\u4e00\u662f\u5171\u8f49\u9304\u6cd5(co-transcription method)\uff0c\u5373\u5728\u8f49\u9304\u904e\u7a0b\u4e2d\u6dfb\u52a0Cap\u985e\u4f3c\u7269\u3002\u53e6\u4e00\u7a2e\u662f\u9175\u7d20\u6cd5\u5c01\u84cb(enzymatic Capping)\u3002\u8f49\u9304\u5f8c\uff0cCap0 \u7531\u75d8\u82d7\u75c5\u6bd2\u52a0\u5e3d\u9176 (VCE)\u3001GTP \u548c S-\u817a\u82f7\u7532\u786b\u6c28\u9178 (SAM) \u9032\u884c\u52a0\u5e3d\u3002\u7136\u5f8c\u900f\u904e 2\u00b4-O-\u7532\u57fa\u8f49\u79fb\u9176\u548c SAM \u5c07 Cap0 \u751f\u6210\u70ba Cap1\u3002 Cap1 \u5c01\u7aef\u4e5f\u53ef\u4ee5\u900f\u904e\u5728\u4e00\u6b65\u904e\u7a0b\u4e2d\u52a0\u5165 VCE\u30012\u00b4-O-\u7532\u57fa\u8f49\u79fb\u9176\u3001GTP \u548c SAM \u4f86\u9032\u884c\u3002 Cap 1\u7d50\u69cb\u6bd4Cap 0\u7d50\u69cb\u66f4\u9069\u5408\u54fa\u4e73\u52d5\u7269\u7cfb\u7d71\uff0c\u4e26\u4e14\u5177\u6709\u66f4\u9ad8\u7684\u8f49\u9304\u6548\u7387\u3002\u6dfb\u52a0 Poly (A) \u5c3e\u5df4\u53ef\u63d0\u9ad8 mRNA \u5728\u9ad4\u5916\u548c\u9ad4\u5167\u7684\u7a69\u5b9a\u6027\u548c\u58fd\u547d\u3002 Poly (A) \u5c3e\u5728\u63d0\u9ad8\u7ffb\u8b6f\u8d77\u59cb\u6548\u7387\u65b9\u9762\u4e5f\u626e\u6f14\u91cd\u8981\u89d2\u8272\u3002<\/p>\n<p><img decoding=\"async\" src=\"https:\/\/biopioneer.com.tw\/wp-content\/uploads\/downloads\/2023\/11\/2-EZ-Cap%E2%84%A2-Cy5-EGFP-mRNA-5-moUTP-APExBIO%E8%B2%A8%E8%99%9F-R1011.png\" \/><\/p>\n<p><img decoding=\"async\" src=\"https:\/\/biopioneer.com.tw\/wp-content\/uploads\/downloads\/2025\/03\/2-EZ-Cap%E2%84%A2-Firefly-Luciferase-mRNA-APExBIO%E8%B2%A8%E8%99%9F-R1018.webp\" \/><\/p>\n<p><img decoding=\"async\" src=\"https:\/\/biopioneer.com.tw\/wp-content\/uploads\/downloads\/2025\/03\/3-EZ-Cap%E2%84%A2-Firefly-Luciferase-mRNA-APExBIO%E8%B2%A8%E8%99%9F-R1018.webp\" \/><\/p>\n<p><img decoding=\"async\" loading=\"lazy\" class=\"\" src=\"https:\/\/biopioneer.com.tw\/wp-content\/uploads\/downloads\/2025\/03\/4-EZ-Cap%E2%84%A2-Firefly-Luciferase-mRNA-APExBIO%E8%B2%A8%E8%99%9F-R1018.webp\" width=\"744\" height=\"609\" \/><\/p>\n<p><a href=\" http:\/\/biopioneer.com.tw\/wp-content\/uploads\/downloads\/2024\/06\/1-ARCA-EGFP-mRNA-APExBIO\u8ca8\u865f-R1001.pdf\"><img decoding=\"async\" loading=\"lazy\" class=\"alignnone\" src=\"http:\/\/biopioneer.com.tw\/wp-content\/uploads\/2023\/02\/COA%E6%96%87%E4%BB%B6_%E5%B7%A5%E4%BD%9C%E5%8D%80%E5%9F%9F-1.jpg\" alt=\"COA\u6587\u4ef6_\u5de5\u4f5c\u5340\u57df 1\" width=\"146\" height=\"60\" \/><\/a><\/p>\n<p><strong style=\"color: #800000;\"><span style=\"font-size: 12pt;\">Product Citation<\/span><\/strong><\/p>\n<div class=\"detail-table \">\n<div class=\"detail-box-cont\">\n<ul id=\"artul\">\n<li><a href=\"https:\/\/doi.org\/10.1002\/adfm.202413220\" target=\"_blank\" rel=\"noopener\">1. Timothy H. Cheung, Alexander Fuchs, et al. &#8220;Acid-Responsive Polymer Additives Increase RNA Transfection from Lipid Nanoparticles.&#8221; ADVANCED FUNCTIONAL MATERIALS Volume35, Issue2 January 9, 2025 2413220<\/a><\/li>\n<li><a href=\"https:\/\/doi.org\/10.1186\/s12951-024-02919-1\" target=\"_blank\" rel=\"noopener\">2. Jingjiao Li, Jie Hu, et al. &#8220;High-throughput synthesis and optimization of ionizable lipids through A3\u00a0coupling for efficient mRNA delivery.&#8221; J Nanobiotechnology. 2024 Nov 4;22(1):672. PMID: 39497197<\/a><\/li>\n<li><a href=\"https:\/\/doi.org\/10.1039\/d4pm00128a\" target=\"_blank\" rel=\"noopener\">3. Caitlin McMillan, Amy Druschitz, et al. &#8220;Tailoring lipid nanoparticle dimensions through manufacturing processes.&#8221; RSC Pharm. 2024 Sep 23 PMID: 39323767<\/a><\/li>\n<li><a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/38437545\" target=\"_blank\" rel=\"noopener\">4. Kathryn A. Whitehead, et al. &#8220;Lipid nanoparticle structure and delivery route during pregnancy dictate mRNA potency, immunogenicity, and maternal and fetal outcomes.&#8221; Proc Natl Acad Sci U S A. 2024 Mar 12;121(11):e2307810121. PMID: 38437545<\/a><\/li>\n<li><a href=\"https:\/\/doi.org\/10.1101\/2024.02.24.581893\" target=\"_blank\" rel=\"noopener\">5. Peng Zhang, Xiaoqing Hu, et al. &#8220;Schlafen-11 and -9 are innate immune sensors for intracellular single-stranded DNA.&#8221; bioRxiv 28 February 2024<\/a><\/li>\n<\/ul>\n<\/div>\n<\/div>\n<p><span style=\"color: #800000;\"><strong><span style=\"font-size: 12pt;\"><a style=\"color: #800000;\" href=\"http:\/\/www.apexbt.com\/\">APExBIO\u53f0\u7063\u4ee3\u7406\u5546<\/a><\/span><\/strong><\/span><\/p>\n<p><span style=\"color: #ff9900;\"><a style=\"color: #ff9900;\" href=\"https:\/\/www.apexbt.com\">https:\/\/www.apexbt.com<\/a><\/span><\/p>\n<p>APExBIO\u63d0\u4f9b\u512a\u8cea\u7684\u80dc\u80bd\u548c\u751f\u7269\u5206\u6790\u8a66\u5291\uff0c\u5ee3\u6cdb\u7522\u54c1\u7dda\u5982Protease\u3001Chromatin\/Epigenetics\u8868\u89c0\u907a\u50b3\u5b78\u3001MAPK Signal\u3001DNA Damege\/DNA repair\u3001\u7d30\u80de\u51cb\u4ea1\u3001\u816b\u7624\u751f\u7269\u5b78\u3001Stem cell\u7b49\u7814\u7a76\u9818\u57df\uff0c \u9084\u63d0\u4f9b\u5b9a\u5236\u7684\u670d\u52d9\uff0c\u5305\u62ec\u591a\u80bd\u5408\u6210\uff0c\u6297\u9ad4\u7684\u751f\u7522\u548c\u6aa2\u6e2c\u7684\u767c\u5c55\u3002\u7522\u54c1\u7ddaDNA\/RNA prep kit\u3001Drug Screening panel\u3001Bioactive peptides\u3001Growth factors\u3001Biotinylation Reagents\u3001tag peptides\u3001amino Acids\u3001Growth factors\u7b49\u3002APExBIO\u7522\u54c1\u8cea\u91cf\u90fd\u4f34\u96a8\u8457\u8b49\u66f8\u7684\u5206\u6790\uff0c\u9ad8\u6548\u6db2\u76f8\u8272\u8b5c\uff0c\u8cea\u8b5c\uff0c\u548cHMNR\u6578\u64da\u3002<\/p>\n<p><a href=\"http:\/\/biopioneer.com.tw\/wp-content\/uploads\/downloads\/2025\/06\/APEXBIO-\u7522\u54c1\u6e05\u55ae2025.pdf\"><img decoding=\"async\" loading=\"lazy\" class=\"alignnone\" src=\"http:\/\/biopioneer.com.tw\/wp-content\/uploads\/2022\/12\/%E5%9E%8B%E9%8C%84%E4%B8%8B%E8%BC%89.gif\" alt=\"\u578b\u9304\u4e0b\u8f09\" width=\"150\" height=\"50\" \/><\/a><\/p>\n<table width=\"1051\">\n<tbody>\n<tr>\n<td width=\"61\">R1001-.1<\/td>\n<td width=\"244\">ARCA EGFP mRNA<\/td>\n<td width=\"746\">Direct-detection reporter mRNA, used as control to study transfection and expression in mammalian cells.<\/td>\n<\/tr>\n<tr>\n<td>R1001-5<\/td>\n<td>ARCA EGFP mRNA<\/td>\n<td>Direct-detection reporter mRNA, used as control to study transfection and expression in mammalian cells.<\/td>\n<\/tr>\n<tr>\n<td>R1001-1<\/td>\n<td>ARCA EGFP mRNA<\/td>\n<td>Direct-detection reporter mRNA, used as control to study transfection and expression in mammalian cells.<\/td>\n<\/tr>\n<tr>\n<td>R1005-.1<\/td>\n<td>Firefly Luciferase mRNA (ARCA, 5mCTP, \u03c8UTP)<\/td>\n<td>Better performance of firefly luciferase mRNA modified by ARCA, 5mCTP and \u03a8UTP, inhibiting RNA-mediated innate immune activation, stable and efficient expression efficiency, used as an experimental control.<\/td>\n<\/tr>\n<tr>\n<td>R1005-5<\/td>\n<td>Firefly Luciferase mRNA (ARCA, 5mCTP, \u03c8UTP)<\/td>\n<td>Better performance of firefly luciferase mRNA modified by ARCA, 5mCTP and \u03a8UTP, inhibiting RNA-mediated innate immune activation, stable and efficient expression efficiency, used as an experimental control.<\/td>\n<\/tr>\n<tr>\n<td>R1005-1<\/td>\n<td>Firefly Luciferase mRNA (ARCA, 5mCTP, \u03c8UTP)<\/td>\n<td>Better performance of firefly luciferase mRNA modified by ARCA, 5mCTP and \u03a8UTP, inhibiting RNA-mediated innate immune activation, stable and efficient expression efficiency, used as an experimental control.<\/td>\n<\/tr>\n<tr>\n<td>R1006-.1<\/td>\n<td>SpCas9 mRNA (ARCA, 5mCTP, \u03c8UTP)<\/td>\n<td>Used with guideRNA for site-specific DNA cleavage in genome editing<\/td>\n<\/tr>\n<tr>\n<td>R1006-5<\/td>\n<td>SpCas9 mRNA (ARCA, 5mCTP, \u03c8UTP)<\/td>\n<td>Used with guideRNA for site-specific DNA cleavage in genome editing<\/td>\n<\/tr>\n<tr>\n<td>R1006-1<\/td>\n<td>SpCas9 mRNA (ARCA, 5mCTP, \u03c8UTP)<\/td>\n<td>Used with guideRNA for site-specific DNA cleavage in genome editing<\/td>\n<\/tr>\n<tr>\n<td>R1007-.1<\/td>\n<td>ARCA EGFP mRNA (5-moUTP)<\/td>\n<td>New modification with better performance &#8212; direct-detection reporter mRNA that suppresses RNA-mediated innate immune activation, used as control to study transfection and expression in mammalian cells.<\/td>\n<\/tr>\n<tr>\n<td>R1007-5<\/td>\n<td>ARCA EGFP mRNA (5-moUTP)<\/td>\n<td>New modification with better performance &#8212; direct-detection reporter mRNA that suppresses RNA-mediated innate immune activation, used as control to study transfection and expression in mammalian cells.<\/td>\n<\/tr>\n<tr>\n<td>R1007-1<\/td>\n<td>ARCA EGFP mRNA (5-moUTP)<\/td>\n<td>New modification with better performance &#8212; direct-detection reporter mRNA that suppresses RNA-mediated innate immune activation, used as control to study transfection and expression in mammalian cells.<\/td>\n<\/tr>\n<tr>\n<td>R1008-.1<\/td>\n<td>ARCA Cy3 EGFP mRNA (5-moUTP)<\/td>\n<td>5-moUTP-modified mRNA with better performance, Cy3 tag, direct-detection reporter mRNA that suppresses RNA-mediated innate immune activation, used as control and tool for determining mRNA delivery and localization.<\/td>\n<\/tr>\n<tr>\n<td>R1008-5<\/td>\n<td>ARCA Cy3 EGFP mRNA (5-moUTP)<\/td>\n<td>5-moUTP-modified mRNA with better performance, Cy3 tag, direct-detection reporter mRNA that suppresses RNA-mediated innate immune activation, used as control and tool for determining mRNA delivery and localization.<\/td>\n<\/tr>\n<tr>\n<td>R1008-1<\/td>\n<td>ARCA Cy3 EGFP mRNA (5-moUTP)<\/td>\n<td>5-moUTP-modified mRNA with better performance, Cy3 tag, direct-detection reporter mRNA that suppresses RNA-mediated innate immune activation, used as control and tool for determining mRNA delivery and localization.<\/td>\n<\/tr>\n<tr>\n<td>R1009-.1<\/td>\n<td>ARCA Cy5 EGFP mRNA (5-moUTP)<\/td>\n<td>5-moUTP-modified mRNA with better performance, Cy5 tag, direct-detection reporter mRNA that suppresses RNA-mediated innate immune activation, used as control and tool for determining mRNA delivery and localization.<\/td>\n<\/tr>\n<tr>\n<td>R1009-5<\/td>\n<td>ARCA Cy5 EGFP mRNA (5-moUTP)<\/td>\n<td>5-moUTP-modified mRNA with better performance, Cy5 tag, direct-detection reporter mRNA that suppresses RNA-mediated innate immune activation, used as control and tool for determining mRNA delivery and localization.<\/td>\n<\/tr>\n<tr>\n<td>R1009-1<\/td>\n<td>ARCA Cy5 EGFP mRNA (5-moUTP)<\/td>\n<td>5-moUTP-modified mRNA with better performance, Cy5 tag, direct-detection reporter mRNA that suppresses RNA-mediated innate immune activation, used as control and tool for determining mRNA delivery and localization.<\/td>\n<\/tr>\n<tr>\n<td>R1010-.1<\/td>\n<td>EZ Cap\u2122 Cy5 Firefly Luciferase mRNA (5-moUTP)<\/td>\n<td>Firefly Luciferase mRNA with Cap 1 structure, modified by 5-moUTP and Cy5-utp, providing higher transcription efficiency and suppressing RNA-mediated innate immune activation<\/td>\n<\/tr>\n<tr>\n<td>R1010-5<\/td>\n<td>EZ Cap\u2122 Cy5 Firefly Luciferase mRNA (5-moUTP)<\/td>\n<td>Firefly Luciferase mRNA with Cap 1 structure, modified by 5-moUTP and Cy5-utp, providing higher transcription efficiency and suppressing RNA-mediated innate immune activation<\/td>\n<\/tr>\n<tr>\n<td>R1010-1<\/td>\n<td>EZ Cap\u2122 Cy5 Firefly Luciferase mRNA (5-moUTP)<\/td>\n<td>Firefly Luciferase mRNA with Cap 1 structure, modified by 5-moUTP and Cy5-utp, providing higher transcription efficiency and suppressing RNA-mediated innate immune activation<\/td>\n<\/tr>\n<tr>\n<td>R1011-.1<\/td>\n<td>EZ Cap\u2122 Cy5 EGFP mRNA (5-moUTP)<\/td>\n<td>EGFP mRNA with Cap 1 structure, modified by 5-moUTP and Cy5-utp, providing higher transcription efficiency and suppressing RNA-mediated innate immune activation<\/td>\n<\/tr>\n<tr>\n<td>R1011-5<\/td>\n<td>EZ Cap\u2122 Cy5 EGFP mRNA (5-moUTP)<\/td>\n<td>EGFP mRNA with Cap 1 structure, modified by 5-moUTP and Cy5-utp, providing higher transcription efficiency and suppressing RNA-mediated innate immune activation<\/td>\n<\/tr>\n<tr>\n<td>R1011-1<\/td>\n<td>EZ Cap\u2122 Cy5 EGFP mRNA (5-moUTP)<\/td>\n<td>EGFP mRNA with Cap 1 structure, modified by 5-moUTP and Cy5-utp, providing higher transcription efficiency and suppressing RNA-mediated innate immune activation<\/td>\n<\/tr>\n<tr>\n<td>R1012-.1<\/td>\n<td>Firefly Luciferase mRNA (ARCA, 5-moUTP)<\/td>\n<td>Better performance of firefly luciferase mRNA modified by ARCA and 5-moUTP, inhibiting RNA-mediated innate immune activation, stable and efficient expression efficiency, used as an experimental control.<\/td>\n<\/tr>\n<tr>\n<td>R1012-5<\/td>\n<td>Firefly Luciferase mRNA (ARCA, 5-moUTP)<\/td>\n<td>Better performance of firefly luciferase mRNA modified by ARCA and 5-moUTP, inhibiting RNA-mediated innate immune activation, stable and efficient expression efficiency, used as an experimental control.<\/td>\n<\/tr>\n<tr>\n<td>R1012-1<\/td>\n<td>Firefly Luciferase mRNA (ARCA, 5-moUTP)<\/td>\n<td>Better performance of firefly luciferase mRNA modified by ARCA and 5-moUTP, inhibiting RNA-mediated innate immune activation, stable and efficient expression efficiency, used as an experimental control.<\/td>\n<\/tr>\n<tr>\n<td>R1013-.1<\/td>\n<td>EZ Cap\u2122 Firefly Luciferase mRNA (5-moUTP)<\/td>\n<td>Firefly Luciferase mRNA with Cap 1 structure, modified by 5-moUTP, providing higher transcription efficiency and suppressing RNA-mediated innate immune activation.<\/td>\n<\/tr>\n<tr>\n<td>R1013-5<\/td>\n<td>EZ Cap\u2122 Firefly Luciferase mRNA (5-moUTP)<\/td>\n<td>Firefly Luciferase mRNA with Cap 1 structure, modified by 5-moUTP, providing higher transcription efficiency and suppressing RNA-mediated innate immune activation.<\/td>\n<\/tr>\n<tr>\n<td>R1013-1<\/td>\n<td>EZ Cap\u2122 Firefly Luciferase mRNA (5-moUTP)<\/td>\n<td>Firefly Luciferase mRNA with Cap 1 structure, modified by 5-moUTP, providing higher transcription efficiency and suppressing RNA-mediated innate immune activation.<\/td>\n<\/tr>\n<tr>\n<td>R1015-.1<\/td>\n<td>EZ Cap\u2122 Cas9 mRNA (5-moUTP)<\/td>\n<td>Used with guideRNA for site-specific DNA cleavage in genome editing.<\/td>\n<\/tr>\n<tr>\n<td>R1015-5<\/td>\n<td>EZ Cap\u2122 Cas9 mRNA (5-moUTP)<\/td>\n<td>Used with guideRNA for site-specific DNA cleavage in genome editing.<\/td>\n<\/tr>\n<tr>\n<td>R1015-1<\/td>\n<td>EZ Cap\u2122 Cas9 mRNA (5-moUTP)<\/td>\n<td>Used with guideRNA for site-specific DNA cleavage in genome editing.<\/td>\n<\/tr>\n<tr>\n<td>R1016-.1<\/td>\n<td>EZ Cap\u2122 EGFP mRNA (5-moUTP)<\/td>\n<td>EGFP mRNA with Cap 1 structure, modified by 5-moUTP\uff0cproviding higher transcription efficiency and suppressing RNA-mediated innate immune activation.<\/td>\n<\/tr>\n<tr>\n<td>R1016-5<\/td>\n<td>EZ Cap\u2122 EGFP mRNA (5-moUTP)<\/td>\n<td>EGFP mRNA with Cap 1 structure, modified by 5-moUTP\uff0cproviding higher transcription efficiency and suppressing RNA-mediated innate immune activation.<\/td>\n<\/tr>\n<tr>\n<td>R1016-1<\/td>\n<td>EZ Cap\u2122 EGFP mRNA (5-moUTP)<\/td>\n<td>EGFP mRNA with Cap 1 structure, modified by 5-moUTP\uff0cproviding higher transcription efficiency and suppressing RNA-mediated innate immune activation.<\/td>\n<\/tr>\n<tr>\n<td>R1017-.1<\/td>\n<td>EZ Cap\u2122 mCherry mRNA (5mCTP, \u03c8UTP)<\/td>\n<td>mCherry mRNA with Cap 1 structure, modified by 5mCTP\/\u03c8UTP, providing higher transcription efficiency and suppressing RNA-mediated innate immune activation.<\/td>\n<\/tr>\n<tr>\n<td>R1017-5<\/td>\n<td>EZ Cap\u2122 mCherry mRNA (5mCTP, \u03c8UTP)<\/td>\n<td>mCherry mRNA with Cap 1 structure, modified by 5mCTP\/\u03c8UTP, providing higher transcription efficiency and suppressing RNA-mediated innate immune activation.<\/td>\n<\/tr>\n<tr>\n<td>R1017-1<\/td>\n<td>EZ Cap\u2122 mCherry mRNA (5mCTP, \u03c8UTP)<\/td>\n<td>mCherry mRNA with Cap 1 structure, modified by 5mCTP\/\u03c8UTP, providing higher transcription efficiency and suppressing RNA-mediated innate immune activation.<\/td>\n<\/tr>\n<tr>\n<td>R1018-.1<\/td>\n<td>EZ Cap\u2122 Firefly Luciferase mRNA<\/td>\n<td>Firefly Luciferase mRNA with Cap 1 structure, providing higher transcription efficiency and enhanced stability.<\/td>\n<\/tr>\n<tr>\n<td>R1018-5<\/td>\n<td>EZ Cap\u2122 Firefly Luciferase mRNA<\/td>\n<td>Firefly Luciferase mRNA with Cap 1 structure, providing higher transcription efficiency and enhanced stability.<\/td>\n<\/tr>\n<tr>\n<td>R1018-1<\/td>\n<td>EZ Cap\u2122 Firefly Luciferase mRNA<\/td>\n<td>Firefly Luciferase mRNA with Cap 1 structure, providing higher transcription efficiency and enhanced stability.<\/td>\n<\/tr>\n<tr>\n<td>R1020-.1<\/td>\n<td>EZ Cap\u2122 EPO mRNA (\u03c8UTP)<\/td>\n<td>Human erythropoietin (EPO) mRNA with Cap 1 structure, modified by \u03c8UTP, providing higher transcription efficiency, and suppressing RNA-mediated innate immune activation.<\/td>\n<\/tr>\n<tr>\n<td>R1020-5<\/td>\n<td>EZ Cap\u2122 EPO mRNA (\u03c8UTP)<\/td>\n<td>Human erythropoietin (EPO) mRNA with Cap 1 structure, modified by \u03c8UTP, providing higher transcription efficiency, and suppressing RNA-mediated innate immune activation.<\/td>\n<\/tr>\n<tr>\n<td>R1020-1<\/td>\n<td>EZ Cap\u2122 EPO mRNA (\u03c8UTP)<\/td>\n<td>Human erythropoietin (EPO) mRNA with Cap 1 structure, modified by \u03c8UTP, providing higher transcription efficiency, and suppressing RNA-mediated innate immune activation.<\/td>\n<\/tr>\n<tr>\n<td>R1021-.1<\/td>\n<td>EZ Cap\u2122 Renilla Luc mRNA<\/td>\n<td>Renilla Luc mRNA with Cap 1 structure, providing higher transcription efficiency and enhanced stability.<\/td>\n<\/tr>\n<tr>\n<td>R1021-5<\/td>\n<td>EZ Cap\u2122 Renilla Luc mRNA<\/td>\n<td>Renilla Luc mRNA with Cap 1 structure, providing higher transcription efficiency and enhanced stability.<\/td>\n<\/tr>\n<tr>\n<td>R1021-1<\/td>\n<td>EZ Cap\u2122 Renilla Luc mRNA<\/td>\n<td>Renilla Luc mRNA with Cap 1 structure, providing higher transcription efficiency and enhanced stability.<\/td>\n<\/tr>\n<tr>\n<td>R1022-.1<\/td>\n<td>EZ Cap\u2122 Renilla Luc mRNA (5-moUTP)<\/td>\n<td>Renilla Luc mRNA with Cap 1 structure, modified by 5-moUTP, providing higher transcription efficiency and suppressing RNA-mediated innate immune activation.<\/td>\n<\/tr>\n<tr>\n<td>R1022-5<\/td>\n<td>EZ Cap\u2122 Renilla Luc mRNA (5-moUTP)<\/td>\n<td>Renilla Luc mRNA with Cap 1 structure, modified by 5-moUTP, providing higher transcription efficiency and suppressing RNA-mediated innate immune activation.<\/td>\n<\/tr>\n<tr>\n<td>R1022-1<\/td>\n<td>EZ Cap\u2122 Renilla Luc mRNA (5-moUTP)<\/td>\n<td>Renilla Luc mRNA with Cap 1 structure, modified by 5-moUTP, providing higher transcription efficiency and suppressing RNA-mediated innate immune activation.<\/td>\n<\/tr>\n<tr>\n<td>R1023-.1<\/td>\n<td>EZ Cap\u2122 Human p53 mRNA<\/td>\n<td>Human p53 mRNA with Cap 1 structure, providing higher transcription efficiency and enhanced stability.<\/td>\n<\/tr>\n<tr>\n<td>R1023-5<\/td>\n<td>EZ Cap\u2122 Human p53 mRNA<\/td>\n<td>Human p53 mRNA with Cap 1 structure, providing higher transcription efficiency and enhanced stability.<\/td>\n<\/tr>\n<tr>\n<td>R1023-1<\/td>\n<td>EZ Cap\u2122 Human p53 mRNA<\/td>\n<td>Human p53 mRNA with Cap 1 structure, providing higher transcription efficiency and enhanced stability.<\/td>\n<\/tr>\n<tr>\n<td>R1024-.1<\/td>\n<td>EZ Cap\u2122 Human p53 mRNA (\u03c8UTP)<\/td>\n<td>Human p53 mRNA with Cap 1 structure, modified by \u03c8UTP, providing higher transcription efficiency and suppressing RNA-mediated innate immune activation.<\/td>\n<\/tr>\n<tr>\n<td>R1024-5<\/td>\n<td>EZ Cap\u2122 Human p53 mRNA (\u03c8UTP)<\/td>\n<td>Human p53 mRNA with Cap 1 structure, modified by \u03c8UTP, providing higher transcription efficiency and suppressing RNA-mediated innate immune activation.<\/td>\n<\/tr>\n<tr>\n<td>R1024-1<\/td>\n<td>EZ Cap\u2122 Human p53 mRNA (\u03c8UTP)<\/td>\n<td>Human p53 mRNA with Cap 1 structure, modified by \u03c8UTP, providing higher transcription efficiency and suppressing RNA-mediated innate immune activation.<\/td>\n<\/tr>\n<tr>\n<td>R1025-.1<\/td>\n<td>EZ Cap\u2122 Human PTEN mRNA<\/td>\n<td>Human PTEN mRNA with Cap 1 structure, providing higher transcription efficiency and enhanced stability.<\/td>\n<\/tr>\n<tr>\n<td>R1025-5<\/td>\n<td>EZ Cap\u2122 Human PTEN mRNA<\/td>\n<td>Human PTEN mRNA with Cap 1 structure, providing higher transcription efficiency and enhanced stability.<\/td>\n<\/tr>\n<tr>\n<td>R1025-1<\/td>\n<td>EZ Cap\u2122 Human PTEN mRNA<\/td>\n<td>Human PTEN mRNA with Cap 1 structure, providing higher transcription efficiency and enhanced stability.<\/td>\n<\/tr>\n<tr>\n<td>R1026-.1<\/td>\n<td>EZ Cap\u2122 Human PTEN mRNA (\u03c8UTP)<\/td>\n<td>Human PTEN mRNA with Cap 1 structure, modified by \u03c8UTP, providing higher transcription efficiency and suppressing RNA-mediated innate immune activation.<\/td>\n<\/tr>\n<tr>\n<td>R1026-5<\/td>\n<td>EZ Cap\u2122 Human PTEN mRNA (\u03c8UTP)<\/td>\n<td>Human PTEN mRNA with Cap 1 structure, modified by \u03c8UTP, providing higher transcription efficiency and suppressing RNA-mediated innate immune activation.<\/td>\n<\/tr>\n<tr>\n<td>R1026-1<\/td>\n<td>EZ Cap\u2122 Human PTEN mRNA (\u03c8UTP)<\/td>\n<td>Human PTEN mRNA with Cap 1 structure, modified by \u03c8UTP, providing higher transcription efficiency and suppressing RNA-mediated innate immune activation.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>\u5831\u544a\u57fa\u56e0mRNA\u7cfb\u5217\u5546\u54c1-&gt;&gt;Firefly Luciferase mRNA APExBIO Te [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":47343,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":[],"categories":[5368],"tags":[6956],"_links":{"self":[{"href":"https:\/\/biopioneer.com.tw\/index.php?rest_route=\/wp\/v2\/posts\/50675"}],"collection":[{"href":"https:\/\/biopioneer.com.tw\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/biopioneer.com.tw\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/biopioneer.com.tw\/index.php?rest_route=\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/biopioneer.com.tw\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=50675"}],"version-history":[{"count":5,"href":"https:\/\/biopioneer.com.tw\/index.php?rest_route=\/wp\/v2\/posts\/50675\/revisions"}],"predecessor-version":[{"id":53860,"href":"https:\/\/biopioneer.com.tw\/index.php?rest_route=\/wp\/v2\/posts\/50675\/revisions\/53860"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/biopioneer.com.tw\/index.php?rest_route=\/wp\/v2\/media\/47343"}],"wp:attachment":[{"href":"https:\/\/biopioneer.com.tw\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=50675"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/biopioneer.com.tw\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=50675"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/biopioneer.com.tw\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=50675"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}